Abstract

The increasing emergence of multidrug-resistant pathogens is one of the biggest threats to human health and food security. The discovery of new antibacterials, and in particular the finding of new scaffolds, is an imperative goal to stay ahead of the evolution of antibiotic resistance. Herein we report the synthesis of a 3-decyltetramic acid analogue of the ureido dipeptide natural antibiotic leopolic acid A. The key step in the synthetic strategy is an intramolecular Lacey–Dieckmann cyclization reaction of a linear precursor to obtain the desired 3-alkyl-substituted tetramic acid core. The synthesized analogue is more effective than the parent leopolic acid A against Gram-positive (Staphylococcus pseudintermedius) and Gram-negative (E. coli) bacteria (MIC 8 µg/mL and 64 µg/mL, respectively). Interestingly, the compound shows a significant activity against Staphylococcus pseudintermedius strains expressing a multidrug-resistant phenotype (average MIC 32 µg/mL on 30 strains tested). These results suggest that this molecule can be considered a promising starting point for the development of a novel class of antibacterial agents active also against resistant strains.

Highlights

  • The treatment of bacterial infections by antibiotics is widely regarded as one of the major achievements of the 20th century

  • The instability of most of the N-unsubstituted 2,3-pyrrolidinediones prepared for the construction of leopolic acid A [4] forced us to develop a linear synthetic strategy consisting of 11 steps, not amenable for the preparation of analogues

  • Aim of this work was the development of a synthetic strategy for obtaining new natural compound-derived scaffolds endowed with increased antimicrobial activity

Read more

Summary

Introduction

The treatment of bacterial infections by antibiotics is widely regarded as one of the major achievements of the 20th century. Leopolic acid A is endowed with antibacterial activity against Staphylococcus aureus and Staphylococcus pseudintermedius with a MIC of 16 μg/mL, and against Escherichia coli with a MIC of 128 μg/mL [3,4]. We planned the synthesis of a leopolic acid A analogue containing the tetramic acid moiety in place of the 2,3-pyrrolidinone ring (compound 1), while maintaining unchanged all the other structural features of the natural compound.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call